Envita’s Approval for Phase I Cancer Study: Some Perspective
Last year, we reported on how Envita had submitted an application to conduct research on natural killer cell therapy after we received a warning letter from the Food and Drug Administration (FDA). Although we regarded our treatment as the practice of medicine and not within FDA’s jurisdiction, we felt that the possibilities presented by the [...]
